157 related articles for article (PubMed ID: 23234835)
1. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.
Mann S; Chintoh A; Giacca A; Fletcher P; Nobrega J; Hahn M; Remington G
Pharmacol Biochem Behav; 2013 Feb; 103(4):717-22. PubMed ID: 23234835
[TBL] [Abstract][Full Text] [Related]
2. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
[TBL] [Abstract][Full Text] [Related]
3. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
[TBL] [Abstract][Full Text] [Related]
4. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.
Fell MJ; Marshall KM; Williams J; Neill JC
J Psychopharmacol; 2004 Jun; 18(2):149-55. PubMed ID: 15260902
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.
Minet-Ringuet J; Even PC; Guesdon B; Tomé D; de Beaurepaire R
Behav Brain Res; 2005 Sep; 163(2):204-11. PubMed ID: 16009434
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
Choi S; DiSilvio B; Unangst J; Fernstrom JD
Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.
Shobo M; Yamada H; Koakutsu A; Hamada N; Fujii M; Harada K; Ni K; Matsuoka N
Life Sci; 2011 Apr; 88(17-18):761-5. PubMed ID: 21356217
[TBL] [Abstract][Full Text] [Related]
8. A model for antipsychotic-induced obesity in the male rat.
Minet-Ringuet J; Even PC; Lacroix M; Tomé D; de Beaurepaire R
Psychopharmacology (Berl); 2006 Sep; 187(4):447-54. PubMed ID: 16783538
[TBL] [Abstract][Full Text] [Related]
9. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
Coccurello R; Caprioli A; Ghirardi O; Conti R; Ciani B; Daniele S; Bartolomucci A; Moles A
Psychopharmacology (Berl); 2006 Jul; 186(4):561-71. PubMed ID: 16758241
[TBL] [Abstract][Full Text] [Related]
11. Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.
Stefanidis A; Watt MJ; Cowley MA; Oldfield BJ
Neuropharmacology; 2017 Sep; 123():55-66. PubMed ID: 28400260
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
Chintoh AF; Mann SW; Lam TK; Giacca A; Remington G
Schizophr Res; 2008 Sep; 104(1-3):23-30. PubMed ID: 18675538
[TBL] [Abstract][Full Text] [Related]
13. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Han M; Deng C; Burne TH; Newell KA; Huang XF
Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
[TBL] [Abstract][Full Text] [Related]
16. Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.
Skrede S; González-García I; Martins L; Berge RK; Nogueiras R; Tena-Sempere M; Mellgren G; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2017 Dec; 20(12):1005-1012. PubMed ID: 29020342
[TBL] [Abstract][Full Text] [Related]
17. No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs.
Cope MB; Jumbo-Lucioni P; Walton RG; Kesterson RA; Allison DB; Nagy TR
Int J Obes (Lond); 2007 Jun; 31(6):1014-22. PubMed ID: 17224931
[TBL] [Abstract][Full Text] [Related]
18. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.
Fell MJ; Anjum N; Dickinson K; Marshall KM; Peltola LM; Vickers S; Cheetham S; Neill JC
Psychopharmacology (Berl); 2007 Oct; 194(2):221-31. PubMed ID: 17581744
[TBL] [Abstract][Full Text] [Related]
19. Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.
Kurbanov DB; Currie PJ; Simonson DC; Borsook D; Elman I
J Psychopharmacol; 2012 Sep; 26(9):1244-51. PubMed ID: 22723540
[TBL] [Abstract][Full Text] [Related]
20. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
